Advances in the development of biomarkers for Alzheimer's disease: From CSF total tau and Aβ1-42 proteins to phosphorylated tau protein

Brain Research Bulletin

Volumn 61, Issue 3, 2003, Pages 243-253

  Hampel, Harald ^a   Goernitz, Alexander ^a   Buerger, Katharina ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Biochemical markers; Dementia therapy; Diagnosis; Mild cognitive impairment (MCI); Neurodegeneration; Progression

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; SERINE; TAU PROTEIN; THREONINE;

AGING; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; CEREBROSPINAL FLUID EXAMINATION; COGNITIVE DEFECT; CONFERENCE PAPER; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR DEPRESSION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR;

EID: 0042090313     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00087-X     Document Type: Conference Paper

References (98)

1. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol. Aging 19 (1998) 109-116.
2. Andersen C., Fabre F.S., Ostberg P., Lannfelt L., Wahlund L. Tau protein in cerebrospinal fluid from semantic dementia patients. Neurosci. Lett. 294:2000;155-158.
3. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56:1999;673-680.
4. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology. 53:1999;1488-1494.
5. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Evaluation of CSF-tau and CSF-A-beta-42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58:2001;373-379.
6. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., Blennow K. Cerebrospinal fluid tau and A-beta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273:1999;5-8.
7. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., Raiha I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry. 64:1998;298-305.
8. Arai H., Higuchi S., Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology. 43:1997;2-10.
9. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., Mattsui T., Morikawa Y., Horikawa E., Kohno H., Sasaki H., Imahori K. CSF Phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166:2000;201-203.
10. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C.M., Mura M., Machida N. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 236:1997;261-264.
11. Arai H., Nakagawa T., Kosaka Y., Higuchi M., Matsui T., Okamura N., Tashiro M., Sasaki H. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals. Alzheimer Res. 3:1997;211-213.
12. Arai H., Satoh-Nakagawa T., Higuchi M., Morikawa Y., Miura M., Kawakami H., Seki H., Takase S., Sasaki H. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci. Lett. 256:1998;174-176.
13. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C.M., Lee V.M.Y., Trojanowski J.Q., Sasaki H. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 38:1995;649-652.
14. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.). 103(1):2002;26-35.
15. Blennow K., Vanmechelen E., Hampel H. CSF total tau, A-beta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24:2001;87-97.
16. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26:1995;231-245.
17. Blomberg M., Jensen M., Basun H., Lannfelt L., Wahlund L.O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci. Lett. 214:1996;163-166.
18. Buerger K., Padberg F., Nolde T., Stübner S., Teipel S.J., Haslinger A., Boetsch T., Sunderland T., Arai H., Rapoport S.I., Möller H.J., Hampel H. CSF tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neurosci. Lett. 277:1999;21-24.
19. Buerger K., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H.-J., Davies P., Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59:2002;627-629.
20. Buerger K., Zinkowski R., Teipel J.S., Arai H., DeBernardis J., Kerkman D., Mc Cullogh C., Padberg F., Faltraco F., Goernitz A., Tapiola T., Rapoport S.I., Pirttilä T., Möller H.J., Hampel H. Differentiation between Geriatric Major Depression and Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am. J. Psychiatry. 160:2003;376-379.
21. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hoffmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttilä T., Scharpiro M.B., Rapoport S.I., Moeller H.-J., Davies P., Hampel H. Differential diagnosis of Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Arch. Neurol. 59:2002;1267-1272.
22. Buhl L., Bojsen-Moller M. Frequency of Alzheimer's disease in a postmortem study of psychiatric patients. Dan. Med. Bull. 35:1988;288-290.
23. Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Beyreuther K., Masters C.L. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 38:1988;1688-1693.
24. Fabre S.F., Forsell C., Viitanen M., Sjogren M., Wallin A., Blennow K., Blomberg M., Andersen C., Wahlund L.O., Lannfelt L. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency but no tau gene mutations. Exp. Neurol. 168:2001;413-418.
25. Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 15:1999;365-375.
26. Galasko D. Biological markers and the treatment of Alzheimer's disease. J. Mol. Neurosci. 17:2001;119-125.
27. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss A., Seubert P. High cerebrospinal fluid tau and low amyloid-beta-42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:1998;937-945.
28. Galasko D., Clark C., Chang L., Miller B., Green R.C., Rotter R., Seubert O. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48:1997;632-635.
29. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. TINS. 16:1993;460-465.
30. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259:1999;133-135.
31. Hampel H., Buerger K., Kohnken R., Teipel S.J., Zinkowski R., Moeller H.J., Rapoport S., Davies P. Tracking of Alzheimer's disease progression with CSF tau protein phosphorylated at threonine 231. Ann. Neurol. 49:2001;545-546.
32. Hampel H., Teipel S.J., Padberg F., Schwarz M.J., Haslinger A., Kötter H.U., Buch K., Dukoff R., Lasser R., Stübner S., Müller N., Sunderland T., Rapoport S.I., Möller H.-J. Discriminant power of combined CSF tau and soluble gp130 in the diagnosis of Alzheimer's disease. Brain Res. 823:1999;104-112.
33. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K. Transient increase in total but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297:2001;187-190.
34. Higuchi M., Tashiro M., Arai H., Okamura N., Hara S., Higuchi S., Itoh M., Shin R.W., Trojanowski J.Q., Sasaki H. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp. Neurol. 162:2000;247-256.
35. Hock C., Golombowski S., Naser W., Müller-Spahn F. Increase levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann. Neurol. 37:1995;414-415.
36. Hu Y.Y., He S.S., Wang X., Duan Q.H., Grundke-Iqbal I., Iqbal K., Wang J. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 160(4):2002;1269-1278.
37. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 52:1999;1555-1562.
38. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;1095-1097.
39. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C.L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271:1996;22908-22914.
40. Iqbal K., Alonso A.C., Gong C.X., Khatoon S., Pei J.J., Wang J.Z., Grundke-Iqbal I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J. Neural Transm. Suppl. 53:1998;169-180.
41. Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J.M., Sato K., Kohno H., Imahori K. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci. Lett. 270:1999;91-94.
42. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., Buerger K., Wiltfang J., Otto M., Kretzschmar H., Moeller H.J., Imagawa M., Kohno H., Nakashima K., Kuzuhara S., Sasaki H., Imahori K. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 50:2001;150-156.
43. Jellinger K.A., Bancher C. AD neuropathology. Neurology. 46:1996;1186-1187.
44. Jensen M., Basun H., Lannfeldt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci. Lett. 186:1995;189-191.
45. Jensen M., Schroeder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.O., Werle E., Jauss M., Beyreuther K., Lannfelt L., Hartmann T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45:1999;504-511.
46. Kahle P.J., Jakowec M., Teipel S.J., Hampel H., Petzinger G.M., Di Monte D.A., Silverberg G.D., Moller H.J., Yesavage J.A., Tinklenberg J.R., Shooter E.M., Murphy G.M. Jr. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 54:2000;1498-1504.
47. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A-beta1-40, and A-beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44:1998;17-26.
48. Kanemaru K., Kameda N., Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology. 54:2000;1875-1876.
49. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry. 71:2001;401-403.
50. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Möller H.J., Davies P., Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287:2000;187-190.
51. Kosunen O., Soininen H., Paljarvi L., Heinonen O., Talasniemi S., Riekkinen P.J. Sr. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. (Berl.). 91:1996;185-193.
52. Kudo T., Mima T., Hashimoto R., Nakao K., Morihara T., Tanimukai H., Tsujio I., Koike Y., Tagami S., Mori H., Nakamura Y., Tanaka T., Mori K., Takeda M. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin. Neurosci. 54:2000;199-202.
53. Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., Guder W. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12:1998;372-377.
54. Letenneur L., Commenges D., Dartigues J.F., Barberger-Gateau P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int. J. Epidemiol. 23:1994;1256-1261.
55. Lim A., Tsuang D., Kukull W., Nochlin D., Leverenz J., McCormick W., Bowen J., Teri L., Thompson J., Peskind E.R., Raskind M., Larson E.B. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J. Am. Geriatr. Soc. 47:1999;564-569.
56. Maruyama M., Arai H., Sugita M., Tanji H., Higuchi M., Okamura N., Matsui T., Higuchi S., Matsushita S., Yoshida H., Sasaki H. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp. Neurol. 172:2001;433-436.
57. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
58. Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D.T., Senin U. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis. Assoc. Disord. 12:1998;211-214.
59. Mitani K., Furiya Y., Uchihara T., Ishii K., Yamanouchi H., Mizusawa H., Mori H. Increased CSF tau protein in corticobasal degeneration. J. Neurol. 245:1998;44-46.
60. Molina L., Touchon J., Herpé M., Lefranc D., Duplan L., Cristol J.P., Sabatier R., Vermersch P., Pau B., Mourton-Gilles C. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport. 10:1999;3491-3495.
61. Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., Usami M., Shoji M., Maruyama S., Hirai S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186:1995;181-183.
62. Morikawa Y., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., Kawakami H., Higuchi M., Okamura N., Tashiro M., Matsui T., Sasaki H. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol. Clin. Exp. Res. 23:1999;575-577.
63. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17:2001;101-118.
64. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., Olson D., Southwick P., Wolfert R., Munroe B., Lieberburg I., Seubert P., Schenk D. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
65. Munroe W.A., Southwick P.C., Chang L., Scharre D.W., Echols C.L. Jr., Fu P.C., Whaley J.M., Wolfert R.L. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann. Clin. Lab. Sci. 25:1995;207-217.
66. Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., Shouji M., Hirai S., Khise K., Tanaka K., Hamamoto M., Yamamoto H., Matsubayashi T., Urakami K., Adachi Y., Nakashima K., Toji H., Nakamura S., Yoshida H. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20:1998;227-235.
67. Nitsch R.M., Rebeck G.W., Deng M., Richardson U.I., Tennis M., Schenk D.B., Vigo-Pelfrey C., Lieberburg I., Wurtman R.J., Hyman B.T., Growdon J.H. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann. Neurol. 37:1995;512-518.
68. Okamura N., Arai H., Higuchi M., Tashiro M., Matsui T., Itoh M., Iwatsubo T., Tomita T., Sasaki H. Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci. Lett. 273:1999;203-207.
69. Okamura N., Arai H., Maruyama M., Higuchi M., Matsui T., Tanji H., Seki T., Hirai H., Chiba H., Itoh M., Sasaki H. Combined analysis of CSF tau levels and [(123)I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am. J. Psychiatry. 159:2002;474-476.
70. Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P., Cepek L., Zerr I., Steinacker P., Windl O., Kornhuber J., Kretzschmar H.A., Poser S., Wiltfang J. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 54:2000;1099-1102.
71. Otto M., Wiltfang J., Cepek L., Neumann M., Mollenhauer B., Steinacker P., Ciesielczyk B., Schulz-Schaeffer W., Kretzsch mar H.A., Poser S. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 58:2002;192-197.
72. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H.A., Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225:1997;210-212.
73. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol. Sci. 22:2001;77-78.
74. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56:1999;303-308.
75. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 212:1996;209-211.
76. Riemenschneider M., Schmolke M., Lautenschlager N., Guder W.G., Vanderstichele H., Vanmechelen E., Kurz A. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284:2000;85-88.
77. Roesler N., Wichart I., Jellinger K.A. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 60:1996;237-238.
78. Samuels S.C., Silverman J.M., Marin D.B., Peskind E.R., Younki S.G., Greenberg D.A., Schnur E., Santoro J., Davis K.L. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology. 52:1999;547-551.
79. Selkoe D.J. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. TINS. 16:1993;403-409.
80. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya V., Okamoto K., Hirai S. Combination assay of CSF Tau, A-beta1-40, A-beta1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158:1998;134-140.
81. Sjogren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelso C., Granerus A.K., Vanderstichele H.V., Blennow K. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 70:2001;624-630.
82. Sjogren M., Minthon L., Davidsson P., Granerus A.K., Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 107:2000;563-579.
83. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 54:2000;1960-1964.
84. Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Skoog I., Wallin A., Wahlund L.O., Marcusson J., Nagga K., Andreasen N., Davidsson P., Vanmechelen E., Blennow K. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 47:2001;1776-1781.
85. Skoog I., Vanmechelen E., Andreasson L.A., Palmertz B., Davidsson P., Hesse C., Blennow K. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy but not to the apolipoprotein E4 allele. Neurodegeneration. 4:1995;433-442.
86. Sunderland T., Wolozin B., Galasko D., Levy J., Dukoff R., Bahro M., Lasser R., Motter R., Lehtimaki T., Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry. 46:1999;750-755.
87. Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., Hirai S., Furiya Y., Endoh R., Mori H. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Sci. 148:1997;41-45.
88. Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P. Sr., Soininen H. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 50:1998;169-174.
89. Tapiola T., Pirttilä T., Mikkonen M., Mehta P.D., Alafuzoff I., Koivisto K., Soininen H. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280:2000;119-122.
90. Tato R.E., Frank A., Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J. Neurol. Neurosurg. Psychiatry. 59:1995;280-283.
91. Urakami K., Mori M., Wada K., Kowa H., Takeshima T., Arai H., Sasaki H., Kanai M., Shoji M., Ikemoto K., Morimatsu M., Hikasa C., Nakashima K. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci. Lett. 259:1999;127-129.
92. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61:1993;1828-1834.
93. E. Vanmechelen, E. Van Kerschaver, K. Blennow, P.P. De Deyn, D. Galasko, L. Parnetti, C.J.M. Sindic, H. Arai, M. Riemenschneider, H. Hampel, H. Pottel, A. Valgaeren, F. Hulstaert, H. Vanderstichele, CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies, in: K. Iqbal, S. Disodia, B. Winblad (Eds.), Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, Wiley, Chichester, 2001, pp. 285-291.
94. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285:2000;49-52.
95. Vanmechelen E., Vanderstichele H., Hulstaert F., Andreasen N., Minthon L., Winblad B., Davidsson P., Blennow K. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech. Ageing Dev. 122:2001;2005-2011.
96. Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., Coria F., Chang L., Miller B., Lieberburg I. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 45:1995;788-793.
97. Vincent I., Zheng J.H., Dickson D.W., Kress Y., Davies P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol. Aging. 19:1998;287-296.
98. Zemlan F.P., Rosenberg W.S., Luebbe P.A., Campbell T.A., Dean G.E., Weiner N.E., Cohen J.A., Rudick R.A., Woo D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J. Neurochem. 72:1999;741-750.